The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study.
Journal
The Lancet. Rheumatology
ISSN: 2665-9913
Titre abrégé: Lancet Rheumatol
Pays: England
ID NLM: 101765308
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
25
03
2024
revised:
20
06
2024
accepted:
26
06
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
31
8
2024
Statut:
aheadofprint
Résumé
Raynaud's phenomenon is the earliest and most common systemic sclerosis manifestation. Episodes can be triggered by cold exposure and ambient temperature changes. Small studies have found that Raynaud's phenomenon outcomes were associated with season. We aimed to map the degree that differences in ambient temperature are associated with Raynaud's phenomenon outcomes across the temperature spectrum. People with Raynaud's phenomenon secondary to systemic sclerosis in the Scleroderma Patient-centered Intervention Network Cohort completed past-week Raynaud's phenomenon severity assessments (0-10 numerical rating scale) at enrolment and longitudinally at 3-month intervals. Mean daily temperature and feels like temperature, which incorporates wind chill and humidity, for the week before each assessment were extracted for each participant from a weather site close to the participant's recruiting centre via the Iowa Environmental Mesonet. We used linear mixed models with basis splines to flexibly model non-linear changes in Raynaud's phenomenon severity across the temperature spectrum. People with lived experience of systemic sclerosis contributed to the study design and interpretation. Between April 15, 2014 and Aug 1, 2023, we included data on 20 233 Raynaud's phenomenon severity assessments from 2243 participants. 1964 (88%) of 2243 participants were women, 279 (12%) were men, and 1813 (82%) were White. Mean age was 54·8 (SD 12·7) years. The maximum predicted Raynaud's phenomenon severity score was 6·8 points (95% CI 5·6-8·1), which occurred at -25°C. Severity scores decreased minimally from -15°C to 5°C (0·05-0·21 points per 5°C difference), then decreased in larger steps between 5°C and 25°C (0·37-0·54 points per 5°C difference). The minimum predicted score was at 25°C (2·6 points [95% CI 2·5-2·7]). Scores increased at temperatures above 25°C to 3·5 points (3·0-4·1) at 35°C and 5·6 points (4·5-6·8) at 40°C. Results were similar for feels like temperature. Raynaud's phenomenon severity is worst at very cold temperatures but also increases with very warm temperatures, presumably due to air conditioning. Clinical management and Raynaud's phenomenon intervention trial designs should consider temperature patterns. Scleroderma Society of Ontario, Scleroderma Canada, Sclérodermie Québec, Scleroderma Manitoba, Scleroderma Atlantic, Scleroderma Association of BC, Scleroderma SASK, Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, the Canadian Institutes of Health Research, the Arthritis Society, the Lady Davis Institute for Medical Research of the Jewish General Hospital, the Jewish General Hospital Foundation, and McGill University.
Sections du résumé
BACKGROUND
BACKGROUND
Raynaud's phenomenon is the earliest and most common systemic sclerosis manifestation. Episodes can be triggered by cold exposure and ambient temperature changes. Small studies have found that Raynaud's phenomenon outcomes were associated with season. We aimed to map the degree that differences in ambient temperature are associated with Raynaud's phenomenon outcomes across the temperature spectrum.
METHODS
METHODS
People with Raynaud's phenomenon secondary to systemic sclerosis in the Scleroderma Patient-centered Intervention Network Cohort completed past-week Raynaud's phenomenon severity assessments (0-10 numerical rating scale) at enrolment and longitudinally at 3-month intervals. Mean daily temperature and feels like temperature, which incorporates wind chill and humidity, for the week before each assessment were extracted for each participant from a weather site close to the participant's recruiting centre via the Iowa Environmental Mesonet. We used linear mixed models with basis splines to flexibly model non-linear changes in Raynaud's phenomenon severity across the temperature spectrum. People with lived experience of systemic sclerosis contributed to the study design and interpretation.
FINDINGS
RESULTS
Between April 15, 2014 and Aug 1, 2023, we included data on 20 233 Raynaud's phenomenon severity assessments from 2243 participants. 1964 (88%) of 2243 participants were women, 279 (12%) were men, and 1813 (82%) were White. Mean age was 54·8 (SD 12·7) years. The maximum predicted Raynaud's phenomenon severity score was 6·8 points (95% CI 5·6-8·1), which occurred at -25°C. Severity scores decreased minimally from -15°C to 5°C (0·05-0·21 points per 5°C difference), then decreased in larger steps between 5°C and 25°C (0·37-0·54 points per 5°C difference). The minimum predicted score was at 25°C (2·6 points [95% CI 2·5-2·7]). Scores increased at temperatures above 25°C to 3·5 points (3·0-4·1) at 35°C and 5·6 points (4·5-6·8) at 40°C. Results were similar for feels like temperature.
INTERPRETATION
CONCLUSIONS
Raynaud's phenomenon severity is worst at very cold temperatures but also increases with very warm temperatures, presumably due to air conditioning. Clinical management and Raynaud's phenomenon intervention trial designs should consider temperature patterns.
FUNDING
BACKGROUND
Scleroderma Society of Ontario, Scleroderma Canada, Sclérodermie Québec, Scleroderma Manitoba, Scleroderma Atlantic, Scleroderma Association of BC, Scleroderma SASK, Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, the Canadian Institutes of Health Research, the Arthritis Society, the Lady Davis Institute for Medical Research of the Jewish General Hospital, the Jewish General Hospital Foundation, and McGill University.
Identifiants
pubmed: 39216493
pii: S2665-9913(24)00189-9
doi: 10.1016/S2665-9913(24)00189-9
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Catherine Fortuné
(C)
Claire E Adams
(CE)
Richard S Henry
(RS)
Ghassan El-Baalbaki
(G)
Kim Fligelstone
(K)
Tracy Frech
(T)
Daphna Harel
(D)
Monique Hinchcliff
(M)
Sindhu R Johnson
(SR)
Maggie Larche
(M)
Catarina Leite
(C)
Christelle Nguyen
(C)
Karen Nielsen
(K)
Janet Pope
(J)
François Rannou
(F)
Tatiana Sofía Rodriguez-Reyna
(TS)
Anne A Shouffoer
(AA)
Maria E Suarez-Almazor
(ME)
Christian Agard
(C)
Laurent Alric
(L)
Marc André
(M)
Floryan Beaslay
(F)
Elana J Bernstein
(EJ)
Sabine Berthier
(S)
Lyne Bissonnette
(L)
Sophie Blaise
(S)
Eva Bories
(E)
Alessandra Bruns
(A)
Carlotta Cacciatore
(C)
Patricia Carreira
(P)
Marion Casadevall
(M)
Benjamin Chaigne
(B)
Lorinda Chung
(L)
Benjamin Crichi
(B)
Thylbert Deltombe
(T)
Christopher Denton
(C)
Tannvir Desroche
(T)
Robyn Domsic
(R)
James V Dunne
(JV)
Bertrand Dunogue
(B)
Regina Fare
(R)
Dominique Farge-Bancel
(D)
Paul R Fortin
(PR)
Loraine Gauzère
(L)
Anne Gerber
(A)
Jessica Gordon
(J)
Brigitte Granel-Rey
(B)
Aurélien Guffroy
(A)
Geneviève Gyger
(G)
Erica Hachulla
(E)
Sabrina Hoa
(S)
Michael Hughes
(M)
Alena Ikic
(A)
Nader Khalidi
(N)
Kimberly Lakin
(K)
Marc Lambert
(M)
David Launay
(D)
Yvonne C Lee
(YC)
Paul Legendre
(P)
Hélène Maillard
(H)
Nancy Maltez
(N)
Joanne Manning
(J)
Isabelle Marie
(I)
Maria Martin Lopez
(M)
Thierry Martin
(T)
Ariel Masetto
(A)
Arsène Mekinian
(A)
Sheila Melchor Díaz
(S)
Morgane Mourguet
(M)
Mandana Nikpour
(M)
Louis Olgane
(L)
Vincent Poindron
(V)
Susanna Proudman
(S)
Grégory Pugnet
(G)
Loïc Raffray
(L)
Alexis Régent
(A)
Frederic Renou
(F)
Sébastien Rivière
(S)
David Robinson
(D)
Esther Rodríguez Almazar
(E)
Sophie Roux
(S)
Perrine Smets
(P)
Vincent Sobanski
(V)
Robert Spiera
(R)
Virginia Steen
(V)
Evelyn Sutton
(E)
Carter Thorne
(C)
Damien Vagner
(D)
John Varga
(J)
Pearce Wilcox
(P)
Mara Cañedo Ayala
(M)
Vanessa Cook
(V)
Cassidy Dal Santo
(C)
Tiffany Dal Santo
(T)
Monica D'Onofrio
(M)
Sophie Hu
(S)
Marieke Alexandra Neyer
(MA)
Sabrina Provencher
(S)
Informations de copyright
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Déclaration de conflit d'intérêts
Declaration of interests JDP has received speaker honoraria or consultancy fees from Astra Zeneca, Boehringer Ingelheim, IsoMab, Janssen, Permeatus, and Sojournix Pharma. MDM has received research grants or contracts from Prometheus Biosciences, Mitsubishi Tanabe, Boehringer Ingelheim, EICOS, Corbus, and Horizon Pharma; consulting fees from Cabaletta Pharma; an honorarium from GSK Pharma; and was a member of a data safety monitoring board or advisory board with Mitsubishi Tanabe, Boehringer Ingelheim, and EICOS. All other authors declare no competing interests.